An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

Summary

The goal of this clinical research study is to learn more about the possible effects of metformin extended release (ER) in patients with colon cancer or adenomas who are about to have surgery. The safety of this drug will also be studied. Metformin-ER is commonly used to control blood sugar levels in patients with diabetes. It is also designed to block a protein in tumor cells that is important in tumor growth and blood vessel development. This may cause cell death or reduce the spread of the disease.

Timeline

Start

2013-05

Primary completion

2014-08

Completion

2014-08

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Accrual”

Drugs

Indications